Editorial comment.
Philippe E
PE
Spiess
D001378:Azasteroids / Q000627:therapeutic use*; D044963:Biopsy, Fine-Needle / Q000379:methods*; D002983:Clinical Competence; D000068538:Dutasteride; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D009367:Neoplasm Staging; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology*; D011786:Quality Control; D018570:Risk Assessment; D015996:Survival Rate; D016896:Treatment Outcome
D001378:Azasteroids; D004791:Enzyme Inhibitors; D000068538:Dutasteride